From Discovery to Application: Biomarkers, Diagnostics, and Molecular Therapeutics in Cancer

This two-day program focuses on new discoveries in the biology of human cancers and their implications for drug development. Experts in bioinformatics and systems biology will discuss the use of new technologies for target identification and mapping oncogenic pathways. Faculty will also address the role of signal transduction, imaging, EGFR inhibition, and tumor hypoxia in the drug discovery, screening, development, and validation processes. The meeting provides a rare gathering of basic and clinical experts in oncology and stem cell biology who will discuss their recent work and the challenges of translating science into therapeutic targets and applications in medicine. In addition, faculty from the biopharmaceutical industry will offer perspectives on clinical development. All attendees will learn the crucial decision gates in drug development that companies consider and that the FDA scrutinizes when evaluating an IND package. This is of particular interest to young investigators focused on the early stages of drug development, who want to see how their discoveries will translate into the clinical realm.